Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug
imexon in combination with an approved drug, gemcitabine, for the treatment of patients with
previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and
gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the
highest doses of the two drugs that can be safely combined together.